Breast cancer patients with positive ultrasound guided axillary node biopsy need dissection

May 3, 2012

Contrary to a trend in treatment, breast cancer patients with suspicious lymph nodes should have an ultrasound-guided axillary node biopsy, and if that biopsy is positive these patients should undergo an axillary dissection, a new study shows.

The study, conducted at the University of Pittsburgh Medical Center, compared 199 patients with a positive ultrasound-guided axillary node biopsy to 434 patients with a positive biopsy. "About 50% of patients with a positive ultrasound-guided axillary node biopsy had substantial lymph node involvement; they were staged pN2 or pN3 at axillary dissection compared to 16% of patients with a positive sentinel node biopsy, said M. Lee Spangler, MD, one of the authors of the study.

"Our results suggest that patients who have a positive ultrasound-guided axillary node biopsy should have an axillary dissection because they have more extensive disease. Patients with a negative ultrasound-guided axillary node biopsy can undergo a instead," said Dr. Spangler.

"In light of the Z0011 trial, some institutions have routinely abandoned ultrasound-guided axillary node biopsy of suspicious axillary nodes in patients who are candidates for sentinel node biopsy alone," said Dr. Spangler. The Z0011 trial found no survival benefit if patients underwent sentinel node biopsy instead of axillary dissection. Sentinel node biopsy is a less extensive surgical procedure.

"Our study indicates that patients with a positive ultrasound-guided axillary node biopsy represent a distinct population and the results of the Z0011 trial probably should not be extrapolated to this group," said Dr. Spangler.

The study will be presented on May 3 at the American Roentgen Ray Society Annual Meeting in Vancouver, Canada.

Explore further: Sentinel node biopsy safe, effective in head and neck melanomas

Related Stories

Sentinel node biopsy safe, effective in head and neck melanomas

August 5, 2011
A common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center.

Sentinel lymph node biopsy predicts outcomes for Merkel cell carcinoma

October 3, 2011
Patients with Merkel Cell Carcinoma who underwent a procedure called sentinel lymph node biopsy (SNLB) had a lower risk of cancer recurrence after two years, according to a study by researchers from Fox Chase Cancer Center. ...

Recommended for you

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.